MD, FASN, FAST

Director, Nephrology & Transplant Immunology and Medical

Director, Kidney Transplant Program at Cedars-Sinai Medical

Dr. Jordan has and continues to be dedicated to improving transplantation rates for highly- human leukocyte antigen (HLA) and ABO blood

group incompatible transplant recipients.

His group has been an innovator in this area with many significant accomplishments. 

Dr. Jordan’s team developed the first desensitization protocol to reduce harmful anti-HLA antibodies in 1990.